02.27.12
EMD Millipore has partnered with Charles River Laboratories to exclusively license its TrueSpike technology to Charles River. The two companies will work to integrate the technology into viral clearance services provided by Charles River. The alliance aims to provide higher purity virus preparations to help ensure validation success and regulatory compliance for biopharma manufacturers.
“This exclusive partnership with Charles River brings together their regulatory and viral clearance experience and our extensive knowledge of virus filtration and process engineering,” said Christophe Couturier, vice president of services and solutions, EMD Millipore. “The increased quality of virus preparations as delivered by TrueSpike technology will help ensure the success of our customers’ validation studies conducted by Charles River.”
“Our goal at Charles River is to provide clients with a complete range of required services that meet their regulatory and scientific needs. This partnership enhances our ability to exceed client expectations by offering a cost-effective, innovative solution that accelerates the production and safety assessment of their biopharmaceutical product,” said Birgit Girshick, corporate vice president of Biopharmaceutical Services at Charles River. “We look forward to working with EMD Millipore to offer this service to our clients through our global network of sites in Cologne and Pennsylvania.”
“This exclusive partnership with Charles River brings together their regulatory and viral clearance experience and our extensive knowledge of virus filtration and process engineering,” said Christophe Couturier, vice president of services and solutions, EMD Millipore. “The increased quality of virus preparations as delivered by TrueSpike technology will help ensure the success of our customers’ validation studies conducted by Charles River.”
“Our goal at Charles River is to provide clients with a complete range of required services that meet their regulatory and scientific needs. This partnership enhances our ability to exceed client expectations by offering a cost-effective, innovative solution that accelerates the production and safety assessment of their biopharmaceutical product,” said Birgit Girshick, corporate vice president of Biopharmaceutical Services at Charles River. “We look forward to working with EMD Millipore to offer this service to our clients through our global network of sites in Cologne and Pennsylvania.”